Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Sagimet Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 was €4.58 Mil. Sagimet Biosciences's Total Assets for the quarter that ended in Mar. 2026 was €93.21 Mil.
Therefore, Sagimet Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 0.05.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Sagimet Biosciences Liabilities-to-Assets Related Terms
Sagimet Biosciences Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0O2 vs EDIT, AUTL, FBRX: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Sagimet Biosciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences (STU:0O2) has a Liabilities-to-Assets of 0.05 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' Liabilities-to-Assets too high?
Sagimet Biosciences' current Liabilities-to-Assets is 0.05. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Liabilities-to-Assets compare to EDIT and AUTL?
Sagimet Biosciences' Liabilities-to-Assets of 0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Liabilities-to-Assets is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Liabilities-to-Assets of 0.05. The current Liabilities-to-Assets is 0.05. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Liabilities-to-Assets is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
